Ravin Ratan, MD, M.Ed.

Peer-Reviewed Articles

1. Bishop AJ, Mitra D, Farooqi A, Swanson DM, Hempel C, Willis T, Pearlnath C, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Guadagnolo BA. Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomes. Cancer 131(1):e35542, 2025. e-Pub 2025. PMID: 39192597.
2. Saab R, Fellman BM, Legarreta AF, Meyer LA, Fleming ND, Ratan R, Nassif Haddad EF, Frumovitz M, Soliman PT. Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study. Gynecol Oncol 191:143-149, 2024. e-Pub 2024. PMID: 39396406.
3. Denu RA, Quintana-Perez CD, Wangsiricharoen S, Ingram DR, Wani KM, Lazar AJ, Ratan R, Roland CL, You YN. DNA Mismatch Repair Deficiency as a Biomarker in Sarcoma. Surg Oncol Insight 1(4), 2024. e-Pub 2024. PMID: 40190387.
4. Gingrich A, Wangsiricharoen S, Torres MB, Ravi V, Ratan R, Keung EZ, Scally CP, Lazar AJ, Wang WL, Roland CL, Hunt KK, Yu W, Torres KE. Clinical Variables Influencing Outcomes in Patients with Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas): Single-Institution Study of 95 Surgical Patients. Ann Surg Oncol 31(12):7950-7956, 2024. e-Pub 2024. PMID: 39150618.
5. Meyers PA, Federman N, Daw N, Anderson PM, Davis LE, Kim A, Macy ME, Pietrofeso A, Ratan R, Riedel RF, Trucco M, Breitmeyer JB, Toretsky JA, Ludwig JA. Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. J Clin Oncol 42(31):3725-3734, 2024. e-Pub 2024. PMID: 38954782.
6. Awad A, Pal K, Yevich S, Kuban JD, Tam A, Odisio BC, Gupta S, Habibollahi P, Bishop AJ, Conley AP, Somaiah N, Araujo DM, Zarzour MA, Ratan R, Roland CL, Keung EZ, Huang SY, Sheth RA. Safety and efficacy of percutaneous image-guided ablation for soft tissue sarcoma metastases to the liver. Cancer 130(15):2703-2712, 2024. e-Pub 2024. PMID: 38642369.
7. Pal K, Awad A, Yevich S, Kuban JD, Tam A, Huang SY, Odisio BC, Gupta S, Habibollahi P, Bishop AJ, Conley AP, Somaiah N, Araujo D, Zarzour MA, Ratan R, Roland CL, Keung EZ, Sheth RA. Safety and Efficacy of Percutaneous Cryoablation for Recurrent or Metastatic Soft Tissue Sarcoma in Adult Patients. AJA, 2024. e-Pub 2024.
8. Nasr LF, Zoghbi M, Lazcano R, Nakazawa M, Bishop AJ, Farooqi A, Mitra D, Guadagnolo BA, Benjamin R, Patel S, Ravi V, Araujo DM, Livingston A, Zarzour MA, Conley AP, Ratan R, Somaiah N, Lazar AJ, Roland C, Keung EZ, Nassif Haddad EF. High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel) 16(9), 2024. e-Pub 2024. PMID: 38730715.
9. Denu RA, Joseph CP, Urquiola ES, Byrd PS, Yang RK, Ratan R, Zarzour MA, Conley AP, Araujo DM, Ravi V, Nassif Haddad EF, Nakazawa MS, Patel S, Wang WL, Lazar AJ, Somaiah N. Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors. Cancers (Basel) 16(9), 2024. e-Pub 2024. PMID: 38730662.
10. Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer 5(4):625-641, 2024. e-Pub 2024. PMID: 38351182.
11. Farooqi AS, Yoder AK, Lin HY, Pasalic D, Erasmus J, Betancourt S, Wernz C, Mitra D, Zarzour MA, Somaiah N, Conley A, Ratan R, Livingston A, Araujo DM, Roland C, Scally C, Keung E, Gandhi SN, Ashleigh Guadagnolo B, Nguyen QN, Bishop AJ. SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. Int J Radiat Oncol Biol Phys 118(4):971-978, 2024. e-Pub 2024. PMID: 37914142.
12. Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah N. Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473266.
13. Roland CL, Nassif Haddad EF, Keung EZ, Wang W, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo B, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour M, Patel S, Benjamin R, Conley AP, Livingston J, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu C, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay J, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nature Cancer, 2024. e-Pub 2024.
14. Nakazawa MS, Livingston JA, Zarzour MA, Bishop AJ, Ratan R, Ludwig JA, Araujo DM, Somaiah N, Ravi V, Nassif EF, Roland CL, Lazar AJ, Guadagnolo BA, Harrison DJ, Benjamin RS, Patel SR, Conley AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors 16:20363613241271669, 2024. e-Pub 2024. PMID: 39105190.
15. Denu RA, Yang RK, Lazar AJ, Patel SS, Lewis VO, Roszik J, Livingston JA, Wang WL, Shaw KR, Ratan R, Zarzour MA, Bird J, Raza S, Akdemir KC, Rodon Ahnert J, Subbiah V, Patel S, Conley AP. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes. Clin Cancer Res 29(23):4844-4852, 2023. e-Pub 2023. PMID: 37747813.
16. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. e-Pub 2023. PMID: 37058010.
17. Palmerini E, Gambarotti M, Italiano A, Nathenson MJ, Ratan R, Dileo P, Provenzano S, Jones RL, DuBois SG, Martin-Broto J, de Alava E, Baldi GG, Grignani G, Ferraresi V, Brunello A, Paoluzzi L, Bertulli R, Hindi N, Montemurro M, Rothermundt C, Cocchi S, Salguero-Aranda C, Donati D, Martin JD, Abdelhamid Ahmed AH, Mazzocca A, Carretta E, Cesari M, Pierini M, Righi A, Sbaraglia M, Laginestra MA, Scotlandi K, Dei Tos AP, Ibrahim T, Stacchiotti S, Vincenzi B. A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl). Eur J Cancer 183:11-23, 2023. e-Pub 2023. PMID: 36791667.
18. Gounder M, Ratan R, Alcindor T, Schoffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. Nirogacestat, a gamma-Secretase Inhibitor for Desmoid Tumors. N Engl J Med 388(10):898-912, 2023. e-Pub 2023. PMID: 36884323.
19. Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med 12(4):4282-4293, 2023. e-Pub 2023. PMID: 36151848.
20. Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res 29(2):401-409, 2023. e-Pub 2023. PMID: 36288393.
21. Lamhamedi-Cherradi SE, Maitituoheti M, Menegaz BA, Krishnan S, Vetter AM, Camacho P, Wu CC, Beird HC, Porter RW, Ingram DR, Ramamoorthy V, Mohiuddin S, McCall D, Truong DD, Cuglievan B, Futreal PA, Velasco AR, Anvar NE, Utama B, Titus M, Lazar AJ, Wang WL, Rodriguez-Aguayo C, Ratan R, Livingston JA, Rai K, MacLeod AR, Daw NC, Hayes-Jordan A, Ludwig JA. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat Commun 13(1):3057, 2022. e-Pub 2022. PMID: 35650195.
22. Hinchcliff E, Rumpf J, Ratan R, Fleming ND, Jazaeri A, Fellman B, Meyer L, Soliman P. Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma. Gynecol Oncol 167(3):490-495, 2022. e-Pub 2022. PMID: 36270831.
23. Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol 23(12):1547-1557, 2022. e-Pub 2022. PMID: 36343656.
24. Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12:1008484, 2022. e-Pub 2022. PMID: 36313661.
25. Nathenson MJ, Hu J, Ratan R, Somaiah N, Hsu R, DeMaria PJ, Catoe HW, Pang A, Subhawong TK, Amini B, Sweet K, Feister K, Malik K, Jagannathan J, Braschi-Amirfarzan M, Sheren J, Caldas Y, Moreno Tellez C, Rosenberg AE, Lazar AJ, Maki RG, Benedetto P, Cohen J, Trent JC, Ravi V, Patel S, Wilky BA. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Clin Cancer Res 28(18):4092-4104, 2022. e-Pub 2022. PMID: 35180772.
26. Subbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res 28(13):2762-2770, 2022. e-Pub 2022. PMID: 35486638.
27. Boyce-Fappiano D, Damron EP, Farooqi A, Mitra D, Conley AP, Somaiah N, Araujo DM, Livingston JA, Ratan R, Keung EZ, Roland CL, Guadagnolo BA, Bishop AJ. Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. Adv Radiat Oncol 7(3):100913, 2022. e-Pub 2022. PMID: 35647398.
28. Gounder MM, Merriam P, Ratan R, Patel SR, Chugh R, Villalobos VM, Thornton M, Van Tine BA, Abdelhamid AH, Whalen J, Yang J, Rajarethinam A, Duh MS, Bobbili PJ, Huynh L, Totev TI, Lax AK, Agarwal S, Demetri GD. Real-world Outcomes of Patients with Locally Advanced or Metastatic Epithelioid SArcoma. Cancer 127(8):1311-1317, 2021. e-Pub 2021. PMID: 33296083.
29. Parkes A, Wang WL, Patel S, Leung CH, Lin H, Conley AP, Somaiah N, Araujo DM, Zarzour M, Livingston JA, Ludwig J, Roland CL, Ravi V, Benjamin RS, Ratan R. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat 186(3):871-882, 2021. e-Pub 2021. PMID: 33575859.
30. Boyce-Fappiano D, Guadagnolo BA, Ratan R, Wang WL, Wagner MJ, Patel S, Livingston JA, Lin PP, Diao K, Mitra D, Farooqi A, Lazar AJ, Roland CL, Bishop AJ. Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma. Oncologist 26(3):250-260, 2021. e-Pub 2021. PMID: 33289298.
31. Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol 21(11):1423-1432, 2020. e-Pub 2020. PMID: 33035459.
32. Tarek N, Said R, Andersen CR, Suki TS, Foglesong J, Herzog CE, Tannir NM, Patel S, Ratan R, Ludwig JA, Daw NC. Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33050651.
33. Bishop AJ, Landry JP, Roland CL, Ratan R, Feig BW, Moon BS, Zarzour MA, Wang WL, Lazar AJ, Lewis VO, Torres KE, Guadagnolo BA. Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. Cancer 126(14):3265-3273, 2020. e-Pub 2020. PMID: 32343846.
34. Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma 2020:8363986, 2020. e-Pub 2020. PMID: 32565716.
35. Bishop AJ, Zarzour MA, Ratan R, Torres KE, Feig BW, Wang WL, Lazar AJ, Moon BS, Roland CL, Guadagnolo BA. Long-term outcomes for patients with desmoid fibromatosis treated with radiation therapy: a 10-year update and re-evaluation of the role of radiation therapy for younger patients. Int J Radiat Oncol Biol Phys 103(5):1167-1174, 2019. e-Pub 2019. PMID: 30552963.
36. Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. JAMA Oncol 4(9):e180219, 2018. e-Pub 2018. PMID: 29800950.
37. Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist 22(10):1271-1277, 2017. e-Pub 2017. PMID: 28710342.
38. Goldberg JD, Zheng J, Ratan R, Small TN, Lai KC, Boulad F, Castro-Malaspina H, Giralt SA, Jakubowski AA, Kernan NA, O'Reilly RJ, Papadopoulos EB, Young JW, van den Brink MR, Heller G, Perales MA. Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. Leuk Lymphoma 58(8):1-13, 2017. e-Pub 2017. PMID: 28073320.
39. Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, Maloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Tamari R, van den Brink MRM, Young JW, O'Reilly RJ, Giralt SA, Perales MA. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34(+) Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 23(1):67-74, 2017. e-Pub 2017. PMID: 27789361.
40. Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst 108(12), 2016. e-Pub 2016. PMID: 27576731.
41. Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq R, Koehne G, Papadopoulos EB, van den Brink MR, Young JW, Boulad F, Kernan NA, O'Reilly RJ, Prockop SE, Yahalom J, Heller G, Perales MA. T Cell-Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission with a Decreased Risk of Graft-versus-Host Disease. Biol Blood Marrow Transplant 19(2):208-213, 2013. e-Pub 2013. PMID: 22982534.
42. Ratan, R, Mason, A, Sinnot, B, Goldfarb, D, Fleming A, R. Drosophila importin a1 performs paralog-specific functions essential for gametogenesis. Genetics(178):839-850, 2008. e-Pub 2008.

Invited Articles

1. Ratan R, Roland CL, Bishop AJ. Desmoid Fibromatosis: Management in an Era of Increasing Options. Curr Oncol Rep 23(4):41, 2021. e-Pub 2021. PMID: 33719012.
2. Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Ludwig JA. IGF-1R/mTOR targeted therapy for Ewing sarcoma: A meta-analysis of five IGF-1R-related trials matched to proteomic and radiologic predictive biomarkers. Cancers (Basel) 12(7):1768, 2020. e-Pub 2020. PMID: 32630797.
3. Bishop AJ, Ratan R, Roland CL. Evolutioni n the management of desmoid tumors: Challenging the role of upfront surgical resection. Bulletin of the American College of Surgeons 104(10), 2019. e-Pub 2019.
4. Ratan R, Patel SR. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?. Curr Treat Options Oncol 18(6):34, 2017. e-Pub 2017. PMID: 28534249.
5. Ratan R, Patel SR. Chemotherapy for Soft Tissue Sarcoma. Cancer 122(19):2952-60, 2016. e-Pub 2016. PMID: 27434055.

Other Articles

1. Kasper B, Baldini EH, Bonvalot S, Callegaro D, Cardona K, Colombo C, Corradini N, Crago AM, Dei Tos AP, Dileo P, Elnekave E, Erinjeri JP, Navid F, Farma JM, Ferrari A, Fiore M, Gladdy RA, Gounder M, Haas RL, Husson O, Kurtz JE, Lazar AJ, Orbach D, Penel N, Ratan R, Raut CP, Roland CL, Schut AW, Sparber-Sauer M, Strauss DC, Van der Graaf WTA, Vitellaro M, Weiss AR, Gronchi A Current Management of Desmoid Tumors: A Review. JAMA Oncol 10(8):1121-1128, 2024. PMID: 38900421.
2. Kasper B, Gounder M, Hernandez L, Baumgarten C, Ratan R Capturing Patient Voice to Improve Outcomes That Matter to Patients with Desmoid Tumor. Cancer Manag Res 16:617-628, 2024. PMID: 38863992.

Abstracts

1. Raj R, Vilson R, Joseph C, Lin H, Munnangi P, Thirasastr P, Nakazawa M, Torres K, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour M, Nassif E, Somaiah N. NF1 and non-NF1 associated Malignant Peripheral Nerve Sheath Tumors (MPNST): the UT MD Anderson (MDACC) experience. ASCO Annual Meeting, 2025. e-Pub 2025.
2. Soewito S, Lin HY, Zoghbi M, Pan C, Young P, Araujo DM, Conley AP, Livingston J, Ludwig JA, Nakazawa M, Ratan R, Ravi V, Somaiah N, Zarzour MA, Patel S, Meyer LA, Soliman PT, Lyu H, Nassif Haddad EF, Denu RA, University of Texas Health Science Center at Houston, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Doxorubicin-based chemotherapy vs gemcitabine/docetaxel in uterine leiomyosarcoma (ULMS). ASCO Annual Meeting, 2025. e-Pub 2025.
3. Denu RA, Zheng Z, Jiang Y, Kochat V, Arslan E, Truong DD, Padron W, Ratan R, Somaiah N, Roland CL, Soliman PT, Meyer LA, Lazar AJ, Nassif Haddad EF, Keung EZ, Rai K. Leiomyosarcoma is characterized by two distinct subtypes driven by NFI or AP1 transcription factors. AACR Annual Meeting, 2025. e-Pub 2025.
4. Arifin AJ, Bishop AJ, Mitra D, Araujo DM, Nassif Haddad EF, Ratan R, Livingston J, Lewis VO, Lin PP, Moon BS, Keung E, Roland CL, Scally C, Guadagnolo B, Farooqi AS. Addressing the Primary Site in Patients with Metastatic Soft Tissue Sarcoma: Is There a role for a Combined Modality Treatment?. CTOS Annual Meeting, 2024. e-Pub 2024.
5. Ravi N, Nakazawa M, Livingston J, Ratan R, Zarzour MA, Conley AP, Araujo D, Ravi V, Somaiah N, Patel S, Nassif Haddad EF. Incidence of germline genetic mutations identified on standard-of-care genomic sequencing for advanced sarcomas. CTOS Annual Meeting, 2024. e-Pub 2024.
6. Mustafayev K, Yepez Guevara E, Pemmaraju N, Jabbour E, Ghayas IC, DiNardo CD, Ratan R, Torres HA. Virologic effect of BCR-ABL tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection. CTOS Annual Meeting, 2024. e-Pub 2024.
7. Arifin AJ, Bishop AJ, Mitra D, Araujo DM, Nassif Haddad EF, Ratan R, Livingston J, Lewis VO, Lin PP, Moon BS, Keung E, Roland CL, Scally C, Guadagnolo B, Farooqi AS. Outcomes following combined modality treatment to the primary site in patients with metastatic soft tissue sarcoma. ASTRO 2024 Annual Meeting, 2024. e-Pub 2024.
8. Munnangi P, King BL, Chiang Y, Conley AP, Araujo DM, Livingston J, Ludwig JA, Nakazawa M, Nassif Haddad EF, Ravi V, Ratan R, Zarzour MA, Patel S, Torres KE, Somaiah N, Texas A&M School of Engineering Medicine, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston TX, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center Hematology/Oncology Fellowship, Houston, TX, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST). ASCO Annual Meeting, 2024. e-Pub 2024.
9. Gingrich AA, Beird H, Segura RL, Denu R, Nakazawa M, Ratan R, Livingston J, Zarzour MA, Conley AP, Somaiah N, Araujo DM, Patel S, Roland CL, Futreal A, Lazar AJ, Keung EZ, Nassif Haddad EF, Rare Tumor Initiative Team, Patient Mosaic Team; The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Immune Infiltrate Analysis Reveals Distinct Immune Class for Leiomyosarcomas. ASCO Annual Meeting, 2024. e-Pub 2024.
10. Palmerini E, Gambarotti M, Connolly EA, Dubois SG, Provenzano S, Martin-Broto J, Italiano A, Kosela-Paterczyk H, Hindi N, Ratan R, Dileo P, Bhadri VA, Jones RL, Haveman L, Grignani G, Kokkali S, Ferraresi V, Rothermundt C, Digklia A, Brunello A, Diaz-Martin J, Katz D, Hofer S, Hong AM, Donati D, Dei Tos AP, Ibrahim T, Vincenzi B, Stacchiotti S. Ultra-Rare Undifferentiated Small Round Cell Sarcoma: How Should We Treat Them? An Analysis Form the Graceful Project. CTOS Annual Meeting, 2023. e-Pub 2023.
11. Gingrich A, Beird H, Chu R, Traweek R, Cope B, Keung EZ, Scally CP, Hunt KK, Torres KE, Roland CL, Initiative Team SPT, Team PM, Futreal P, Bishop A, Guadagnolo B, Mitra D, Farooqi A, Araujo D, Alejandra Zarzour AM, Livingston J, Conley A, Patel S, Ravi V, Somaiah N, Lazar AJ, Ratan R, Nassif EF. Leiomyosarcoma intratumoral macrophage infiltrates are associated with distinct clinical and genomic presentations. CTOS Annual Meeting, 2023. e-Pub 2023.
12. Agulink M, Tap WD, Cote GM, Ratan R, Khan S, Chawla SP, Attia S, Elias AD, Milhem M, Pressey J, Ali A, Mintautas I, Huan Liu RL, Hurh E, Neville K, Van Tine BA. A Phase 1 Study of CFT8634, A Novel Bifuctional Degradation Activating Compound (BIDAC) Degrader of BRD9, in Synovial Sarcoma and SMARCB1-NULL Tumors. CTOS Annual Meeting, 2023. e-Pub 2023.
13. Jones RL, Gounder M, Chugh R, Agulnik M, Singh A, Van Tine BA, Andelkovic V, Choy E, Lewin J, Ratan R, Ball HA, Yovell JY, Gordon G, Gutierrez A, Kasper B. Phase 2 Results From the Ringside Phase 2/3 Trial of AL102 for Treatment of Desmoid Tumors. CTOS Annual Meeting, 2023. e-Pub 2023.
14. Bishop AJ, Mitra D, Farooqi AS, Hempel C, Bagchi C, Willis T, Pearlnath C, Wang W, Ratan R, Somaiah N, Benjamin R, Torres KE, Hunt K, Scally C, Satcher RL, Jr, Bird J, Lin P, Moon B, Lewis V, Roland C, Guadagnolo B. Long-Term Disease Outcomes, Late Toxicity, And Function Following Hypofractionated Preoperative Radiation Therapy For Patients With Soft Tissue Sarcomas: A HYPORT-STS Update. CTOS Annual Meeting, 2023. e-Pub 2023.
15. Truong DD, Arsian E, Kochat V, Krishnan S, Agyemang CN, Divenko M, Ingram DR, Segura RL, Basi A, Gomez J, Beird H, Wu C, Burks J, Futreal P, Lazar AJ, Ratan R, Daw NC, Hayes-Dixon A, Rai K, Ludwig JA. Multi-Omic Analysis of Desmoplastic Small Round Cell Tumors Reveal Distinct Lineages. CTOS Annual Meeting, 2023. e-Pub 2023.
16. Torres MB, Leung CH, Keung E, Feng C, Beird H, Zarzour A, Scally C, Hunt K, Conley A, Bishop A, Guadagnolo B, Farooqi A, Mitra D, Araujo D, Livingston A, Ratan R, Patel S, Ravi V, Lazar A, Roland CL, Somaiah N, Nassif EF. Dedifferentiated Liposarcomas Treated With Immune Checkpoint Blockade: The MD Anderson Experience. CTOS Annual Meeting, 2023. e-Pub 2023.
17. Livingston J, Cloutier J, Conley AP, Gorlick R, Benjamin RS, Posey K, Nassif E, Zarzour M, Araujo D, Ratan R, Ravi V, Somaiah N, Lin H, Leung CH, Lazar AJ, Lewis VO, Lin P, Amini B, Valenzuela RF, Patel S, Wang W. Chemotherapy and Prognostic Significance of Extent of Dedifferentiation in Dedifferentiated Parosteal Osteosarcoma. CTOS Annual Meeting, 2023. e-Pub 2023.
18. Denu RA, MD, PhD, Joseph CP, Urquiola ES, Byrd PS, Ratan R, MD, MEd, Zarzour MA, MD, Conley AP, MD, Araujo D, MD, Ravi V, MD, MS, MBA, Patel S, MD, Wang W, MD, Lazar AJ, MD, PhD, Somaiah N, MD. Clinico-Genomic Analysis of KIT/PDGFRA/SDH Wild-Type Gatrointestinal Stromal Tumors Identifies Potential Driver Mutations. CTOS Annual Meeting, 2023. e-Pub 2023.
19. Nassif EF, Beird H, Mitra A, Liu B, McBride K, Wang W, Ingram D, Wani K, Keung EZ, Initiative Team RT, Team PM, Zarzour A, Conley A, Araujo D, Livingston J, Ratan R, Patel S, Ravi V, Benjamin R, Lazar AJ, Roland CL, Futreal P, Somaiah N. Histology Specific Intratumoral B-Cell Biology in Alveolar Soft-Part Sarcomas (ASPS) in Response to Durvalumab-Tremelimumab (D-T). CTOS Annual Meeting, 2023. e-Pub 2023.
20. Denu RA, Yang RK, Lazar AJ, Patel SS, Lewis V, Roszik J, Livingston J, Wang W, Shaw KR, Ratan R, Zarzour M, Byrd J, Raza SM, Akdemir KC, Ahnert JR, Subbiah V, Patel S, Conley A. Clinico-Genomic Profiling of Convetional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to be Associated With Worse Outcomes. CTOS Annual Meeting, 2023. e-Pub 2023.
21. Roszik J, Denu RA, Nassif EF, Nakazawa MS, Livingston J, Akdemir KC, Ratan R, Lazar AJ, Wang W, Pestana R, Farooqi A, Roland C, Keung EZ, Ravi V, Somaiah N, Patel S, Conley AP. TP53 Alterations in Sarcomas: An Analysis From the AACR-GENIE Database. CTOS Annual Meeting, 2023. e-Pub 2023.
22. Kasper B, Gounder M, Ratan R, Bell T, Ivanescu C, Marcus J, Lim A, Goble S, Cho S, Alcindor T, der Graaf WV, Schoffski P, Wilky B, Benson C, Bui N, Chugh R, Kummar S, Riedel R. Impact of Nirogacestat on Functional Status in Patients With Desmoid Tumors: Results From the Phase 3 DEFI Study. CTOS Annual Meeting, 2023. e-Pub 2023.
23. Chugh R, Chawla SP, Spira A, Subbiah V, Hartner L, Wilky B, Lakhani N, Lieu C, Ratan R, O'Neill B, Andrianow V, Piccione EC, Kalabus J, Willis KM, Eckelman B, Grohar PJ. The Tetravalent Death Receptor 5 Agonist INBRX-109 Combined With Chemotherapy in Ewing Sarcoma: Preliminary Data From a Phase 1 Study. CTOS Annual Meeting, 2023. e-Pub 2023.
24. Alcindor T, Kasper B, Gounder MM, Ratan R, Der Graaf WTV, Wilky BA, Riedel RF, Federman N, Peruzzi A, Moody S, Lim A, Tumminello B, Kummar S, Schöffski P. Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors. ASCO Annual Meeting, 2023. e-Pub 2023.
25. Gounder MM, Jones RL, Chugh R, Agulnik M, Singh AS, Van Tine BA, Andelkovic V, Choy E, Lewin JH, Ratan R, Gordon GB, Yovell J, Gutierrez AA, Kasper B. RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results. ASCO Annual Meeting, 2023. e-Pub 2023.
26. Der Graaf WTV, Gounder MM, Ratan R, Ivanescu C, Marcus J, Bell T, Lim A, Smith L, Oton AB, Alcindor T, Schöffski P, Wilky BA, Riedel RF, Benson C, Bui N, Chugh R, Kummar S, Kasper B. Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study. ASCO Annual Meeting, 2023. e-Pub 2023.
27. Thirasastr P, Lin HY, Nassif EF, Wang W, Araujo DM, Benjamin RS, Conley AP, Livingston J, Ludwig JA, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Clinical implications of recurring mutations in myxoid liposarcoma (MLS). ASCO Annual Meeting, 2023. e-Pub 2023.
28. Gounder MM, Ratan R, Alcindor T, Schöffski P, der Graaf WTV, Wilky BA, Riedel RF, Lim A, Smith L, Moody S, Attia S, Chawla SP, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Kummar S, Kasper B. A Phase 3, Randomized Double-Blind Trial of Nirogacestat versus placebo for Progressing Desmoid Tumors/Aggressive Fibromatosis. CTOS Annual Meeting, 2022. e-Pub 2022.
29. Truong DD, Lamhamedi-Cherradi S, Maitituoheti M, Beird H, Wu C, Krishnan S, Ingram DR, McCall D, Cuglievan B, Futreal P, Titus M, Lazar A, Wang W, Rai K, MacLeod A, Ratan R, Livingston J, Daw NC, Hayes-Jordan A, Ludwig JA. The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT. CTOS Annual Meeting, 2022. e-Pub 2022.
30. Gill J, Conley AP, Somaiah N, Araujo DM, Ratan R, Posey K, Benjamin RS, Patel S, Daw NC, Harrison DJ, Gorlick R, Lin H, Wang W, Amini B, Gordon N, Livingston J. A Phase 1/2 Trial of Gemcitabine, Docetaxel, and Hydroxychloroquine in Advanced / Metastatic Osteosarcoma: Results of Phase 1. CTOS Annual Meeting, 2022. e-Pub 2022.
31. Thirasastr P, Joseph C, Araujo DM, Benjamin RS, Conley AP, Livingston J, Ludwig JA, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Outcomes in late-line systemic treatment in GISTs: Does sequence matter?. ASCO Annual Meeting, 2022. e-Pub 2022.
32. Nakazawa M, Livingston J, Bishop AJ, Zarzour MA, Somaiah N, Ratan R, Gill JB, Urquiola E, Posey K, Guadagnolo BA, Gorlick RG, Benjamin RS, Patel S, Conley AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma (ARMS) patients on front-line therapies: An MD Anderson Cancer Center (MDACC) case series. ASCO Annual Meeting, 2022. e-Pub 2022.
33. Keung EZ, Nassif EF, Lin HY, Lazar AJ, Torres KE, Wang W, Guadagnolo BA, Bishop AJ, Hunt K, Feig BW, Bird JE, Lewis VO, Ratan R, Patel S, Zelazowska M, Liu B, McBride K, Wargo JA, Roland CL, Somaiah N. Randomized phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS): Survival results after 2 years of follow-up and intratumoral B-cell receptor (BCR) correlates. ASCO Annual Meeting, 2022. e-Pub 2022.
34. Somaiah N, Livingston J, Ravi V, Lin HY, Amini B, Solis LM, Conley AP, Zarzour MA, Ludwig JA, Ratan R, Wang W, Araujo DM, Patel S, Roland CL, Lazar AJ, Gorlick RG, Parra ER, Haymaker CL. A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes. ASCO Annual Meeting, 2022. e-Pub 2022.
35. Cranmer LD, Abdul Razak AR, Ratan R, Choy E, George S, Liebner DA, Stenehjem DD, Gounder MM. Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor. ASCO Annual Meeting, 2022. e-Pub 2022.
36. Ludwig JA, Federman NC, Anderson PM, Macy ME, Riedel RF, Davis LE, Daw NC, Wulff J, Kim A, Ratan R, Baskin-Bey ES, Toretsky JA, Breitmeyer JB, Meyers PA. TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results. ASCO Annual Meeting, 2021. e-Pub 2021.
37. Ludwig JA, Federman N, Anderson P, Macy ME, Davis LE, Riedel RF, Muscal JA, Daw NC, Ratan R, Toretsky J, Ianopulos X, Hsu FJ, Breitmeyer JB, Meyers P. Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma. ESMO Annual Meeting, 2020. e-Pub 2020.
38. Subramaniam A, Zheng J, Yalamanchili S, Conley AP, Ratan R, Somaiah N, Livingston JA, Zarzour MA, Araujo DM, Benjamin RS, Patel S, Ravi V. Modulation of YAP/TAZ by statins to improve survival in epithelioid hemangioendothelioma (EHE). J Clin Oncol 38, 2020. e-Pub 2020.
39. Hinchcliff E, Rumpf J, Ratan R, Fleming ND, Jazaeri AA, Pitcher P, Soliman PT. Present-day management of uterine leiomyosarcoma: Evaluation and treatment sequencing and other prognostic factors. J Clin Oncol 38(suppl), 2020. e-Pub 2020.
40. Somaiah N, Conley AP, Lin HY, Amini B, Sabir S, Araujo DM, Benjamin RS, Livingston JA, Patel S, Ratan R, Ravi V, Zarzour MA, Wang WL, Tate T, Roland CL, Daw NC, Futreal A, Lazar AJ, Wistuba II, Hwu P. A phase II multi-arm study of durvalumab and tremilimumab for advanced or metastatic sarcomas. J Clin Oncol 38(suppl), 2020. e-Pub 2020.
41. Roland CL, Keung EZ, Lazar AJ, Torres KE, Wang WL, Guadagnolo A, Bishop AJ, Lin HY, Feig BW, Bird JE, Lewis VO, Tawbi HA, Ratan R, Patel S, Wargo JA, Somaiah N. Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). J Clin Oncol 38(suppl), 2020. e-Pub 2020.
42. Gounder MM, Stachiotti S, Schoffski P, Cote GM, Villalobos VM, Jahan MJ, Chen TW, Ratan R, Gupta AA, Dileo P, Agulnik M, Italiano A, Attia S, Mir O, Pressey JG, Sierra L, Lingaraj T, Yang J, Agarwal S, Jones RL. Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma. J Clin Oncol 38(suppl), 2020. e-Pub 2020.
43. Gounder M, Schoffski P, Stachiotti S, Villalobos V, Chugh R, Agulnik M, Attia S, Chen TW, Gupta A, Jahan T, Jones R, Italiano A, Blay JY, Cote JM, Demetri G, Loggers E, Ratan R, Fouladi M, Macy M, Makin G, Clawson A, Daigle S, Mencio C, Sapir I, Bourdeat F. EZH2 inhibitor tazemetostat (taz) interim data in in adults and pediatric patients with INI-1 negative soft-tissue sarcomas (STS) including epithelioid sarcoma (ES). CTOS Annual Meeting, 2018. e-Pub 2018.
44. Stacchiotti, S, Blay JY, Jones RL, Demetri G, Italiano A, Thomas D, Chen TW, Schoffski P, Gil T, Jahan T, Cote G, Ratan R, Attia S, Roche M, Daigle S, Sapir I, Clawson A, Gounder M. A phase II, multicenter study of the EZH2 inhbitor tazemetostat in adults (INI-1 negative tumors cohort)(NCT02601950). Annals of Oncology 29(suppl_8), 2018. e-Pub 2018.
45. Parkes AM, Patel S, Leung CH, Lin HY, Conley AP, Somaiah N, Araujo DM, Zarzour MA, Livinston JA, Ludwig J, Ravi V, Benjamin R, Ratan R. Systemic therapy regimen outcomes in metastatic phyllodes tumor of the breast. ASCO Annual Meeting suppl, 2018. e-Pub 2018.
46. Subbiah V, Sankala KK, Ratan R, Garcia ES, Valentina B, Gil T, Villalobos V, Chawla S, Lardelli P, Siguero M, Kahatt CM, Sotos-Matos A, Ferrari S. Efficacy and Safety of Lurbinectedin (PM1183) in Ewing Sarcoma: Final Results from a phase 2 study. J Clin Oncol 36(suppl), 2018. e-Pub 2018.
47. Ratan R, Livingston JA, Wang W, Zarzour MA, Patel SR. CIC rearranged sarcomas: The MD Anderson experience with a rare, recently recognized entity. CTOS Annual Meeting, 2017. e-Pub 2017.
48. Frezza AM, Asano N, Jones R, Ratan R, Teterycz P, Gelderblom H, Boye K, Brahmi M, Palmerini E, Hindi N, Brunello A, Desar I, Grignani G, Fedenko AA, Vicenzi B, Papai Z, Kawai A, Lo Vullo S, Casali PG, Stachiotti S. Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-insitutional case series. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
49. Conley AP, Huh WW, Roszik J, Harrison DJ, Hayes-Jordan AA, Kehr KA, Ratan R, Somaiah N, Ravi V, Araujo DM, Zarzour MA, Ludwig JA, Wang WL, Benjamin RS, Patel S. Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies: An MD Anderson Cancer Center (MDACC) series. J Clin Oncol 34(suppl), 2017. e-Pub 2017.
50. Conley AP, Huh WW, Roszik J, Harrison DJ, Hayes-Jordan AA, Kehr KA, Ratan R, Somaiah N, Ravi V, Araujo DM, Zarzour MA, Ludwig JA, Wang W, Benjamin RS, Patel S. Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies: An MD Anderson Cancer Center (MDACC) series. ASCO Annual Meeting, 2016. e-Pub 2016.
51. Nathenson MA, Conley AP, Ratan R, Zarzour MA, Somaiah N, Araujo DM, Patel S, Benjamin RS, Ravi V. Efficacy of front-line chemotherapy for recurrent/metastatic adenosarcoma of the uterus. J Clin Oncol 34(suppl), 2016. e-Pub 2016.

Book Chapters

1. Hinchcliff, EM, Lawson, BC, Ratan, R, Soliman, PT. Uterine leiomyosarcoma. In: Diagnosis and Treatment of Rare Gynecologic Cancers. Elsevier Health Sciences, 145-160, 2023.
2. Ratan R. Sarcoma. In: ASCO-Self Evaluation Program. 2023. American Society of Clinical Oncology, 2023.
3. Ratan R, Benjamin RS. Sarcomas of the Skull Base. In: Comprehensive Management of Skull Base Tumors. 2nd. Thieme, 2021.
4. Ratan R, Patel SR. Medical Oncology. In: Sarcomas: Evidence-Based Diagnosis and Management. 1. Springer, 2020.
5. Ratan R, Ater J, Reiber AG, Rodriguez MA. Long-term survivorship in Adult and Pediatric Cancer. In: In: MD Anderson Manual of Medical Oncology. 3, 2016.

Letters to the Editor

1. Mustafayev K, Yepez Guevara E, DiNardo CD, Jabbour E, Ghayas IC, Ratan R, Pemmaraju N, Torres HA. Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study. Leuk Res 147: 107597, 2024.